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PAYMENTS FOR ACUTE MYOCARDIAL INFARCTION EPISODES OF CARE
BY HOSPITAL INTERVENTIONAL CAPABILITY
Gal Ben-Josef, Lesli S. Ott, Steven B. Spivack, Changqin Wang, Sachin J. Shah, Jeptha P. Curtis,
Nancy Kim, Harlan M. Krumholz, Susannah M. Bernheim, and Joseph S. Ross. Department of
General Internal Medicine, Yale University School of Medicine, New Haven, CT.
It is not known whether hospitals with percutaneous coronary intervention (PCI)
capability provide more costly care than hospitals without PCI capability for patients admitted for
acute myocardial infarction (AMI). The growing number of PCI-capable hospitals and higher rate
of PCI use at technologically advanced hospitals may result in higher costs for episodes of care
initiated at PCI hospitals. However, higher rates of transfers and post-acute care procedures may
result in higher costs for episodes of care initiated at non-PCI hospitals.
We identified all AMI admissions in 2008 among Medicare fee-for-service beneficiaries
and classified hospitals as PCI- or non-PCI-capable based on hospitals’ 2007 PCI performance.
We added all payments from the time of admission through 30 days post-admission, including
payments to hospitals other than the admitting hospital. We calculated and compared riskstandardized payment for PCI and non-PCI hospitals using 2-level hierarchical generalized linear
models that adjust for patient demographics and clinical characteristics. PCI hospitals had a
slightly higher mean 30-day risk-standardized payment than non-PCI hospitals ($20,340 v.
$19,713, P<0.001). Patients presenting to PCI hospitals had higher PCI rates (39.2% v. 13.2%,
P<0.001) and higher coronary artery bypass graft (CABG) rates (9.5% v. 4.4%, P<0.001) during
index AMI admissions, lower transfer rates (2.2% v. 25.4%, P<0.001), and lower
revascularization rates within 30 days (0.15% v. 0.27%, P<0.0001) than those presenting to nonPCI hospitals.
Despite higher PCI and CABG rates for patients who began their 30-day episode of care
at PCI hospitals, PCI hospitals were only $627 more costly than non-PCI hospitals for the
treatment of patients with AMI.
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INTRODUCTION
In recent years, hospitals have increasingly established new programs for
percutaneous coronary intervention (PCI). In 2001, approximately 25% of hospitals in the
United States offered primary PCI and by 2006, this number had grown to 36% of
hospitals, an increase of 44%.1 The number of hospitals offering diagnostic angiography
and coronary artery bypass graft (CABG) surgery has also risen, though more gradually,
with an increase of 3% and 4% from 1996 to 2008, respectively.2 The increase in the
number of hospitals with invasive capabilities, and PCI-capable hospitals (PCI hospitals)
in particular, may have implications for both the quality and cost of care for patients with
acute myocardial infarction (AMI). Several key issues include the distribution of patients
over more hospitals, leading to lower volume of patients with AMI treated at each
hospital and fewer experts in AMI care per hospital, greater variation in patient
management and outcomes, and the potential for overutilization of PCI in the absence of
clear medical indications. Despite these concerns, invasive cardiac facilities are profitable
and prestigious, so investing in these services is appealing to hospitals even if the new
facilities will not substantially increase access to care and may in fact exacerbate the
growing cost of medical care in the U.S.2

Access to Care
Despite the increase in the number of PCI hospitals, several recent studies have
shown little to no improvement in access to emergent or elective procedures.1-4 For
example, Concannon et al. demonstrated that a 16.5% expansion in PCI programs
between 2004 and 2008 increased access to timely PCI in only 1.8% of the U.S.
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population.3 Similarly, Horwitz et al. found disproportionately small changes in access to
coronary angiography, PCI, and CABG between 1996 and 2008 given the associated
increase in capable facilities, with increases of 1%, 5%, and 4% of the population with
access to the respective procedures.2 It follows that rates of both emergent and elective
procedures remained constant between 2001 and 2008, despite the growing number of
available PCI programs.4 One explanation for this incongruity is that hospitals located in
areas with existing PCI programs were more likely to open new PCI facilities than
hospitals located in areas without PCI programs,3 even when these same services were
already offered within a 40 mile radius.2 This trend is likely explained by the fact that
these services are well reimbursed and draw both patients and physicians to the hospital,
making the expansion profitable.
Similar trends have been documented for cardiac surgery programs.5 Between
1993 and 2004, the creation of 301 new cardiac surgery programs – a 30% increase – was
not associated with an increase in the number of CABG surgeries performed; rather, the
number of CABG surgeries has been decreasing since 1997. Of the new programs, 42%
were located in communities where cardiac surgery was already accessible.5
However, the discrepancy between availability and access is not consistent across
the country. Concannon et al. have shown that there exists significant regional variation
in access to PCI, ranging from 88% of the population with access to PCI in the Northeast
to 76% in the South, with minimal improvement between 2001 and 2006.1 Nevertheless,
in areas with lower rates of access to PCI in 2004, new programs did significantly
improve access to PCI for patients with ST-elevation myocardial infarction (STEMI),
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suggesting that patients living in underserved areas may benefit from the expansion of
hospital PCI capabilities.3

Quality of Care
The growth of PCI capability in the U.S. has also spurred investigations into
quality of care, including studies on appropriate use of PCI, the effect on and implications
of hospital PCI volume and time to treatment, and most importantly, patient outcomes
such as rates of mortality and readmissions.

Appropriate Use of PCI
Many studies have shown that the availability of invasive cardiac procedures at a
facility is associated with increased utilization of these procedures both during the initial
hospitalization6-9 and within 30 days of hospital admission.10 In a 1998 study, Krumholz
et al. demonstrated that hospitals with cardiac catheterization facilities had a
catheterization rate of 39%, compared with a rate of only 27% at hospitals without on-site
catheterization facilities, despite adjustments for baselines patient characteristics.8
Though the study found similar rates of revascularization between hospitals,8 a similar
study by Alter et al. found an 8% difference in the rates of revascularization between
patients admitted to hospitals with and without on-site catheterization capabilities.7 More
recently, Nallamothu et al. evaluated the relationship between opening of new specialty
cardiac hospitals or new cardiac programs at general hospitals and rates of coronary
revascularization, finding that changes in revascularization rates in regions with new
cardiac hospitals far outstripped rates in areas with new programs in general hospitals and
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in areas with no new programs.9 However, in cardiac hospitals, rates of revascularization
held steady in patients with AMI while use of the procedure in patients without AMI
increased, calling into question the appropriateness of these procedures. The authors
raised concerns that physician ownership of cardiac hospitals may result in stronger
financial incentives for providing unnecessary procedures.
Given that more PCIs are performed for patients admitted to PCI hospitals, it is
important to consider whether these procedures are medically appropriate. PCI is an
invasive procedure that may expose patients to undue risk without significant benefit if
performed in inappropriate cases. Additionally, as cardiac services can contribute 25-40%
of hospital revenues,5 many researchers have questioned whether increasing rates of
invasive cardiac procedures may be attributed in part to overutilization spurred by
procedure availability or other underlying incentives. Accordingly, the American College
of Cardiology Foundation (ACCF), in conjunction with several professional
organizations, developed appropriateness criteria for coronary revascularization in 2009
for the treatment of coronary artery disease (CAD), with approximately 180 common
clinical scenarios rated on an appropriateness scale of 1 to 9 based on symptoms, prior
use of medical therapy, risk level, and coronary anatomy.11 Based on these criteria, Chan
et al. conducted a study in 2011 to assess the appropriateness of PCI.12 Of approximately
70% of PCIs performed for acute indications – including STEMI, non-ST-segment
elevation myocardial infarctions (NSTEMI), and unstable angina (UA) with high-risk
features – nearly 99% were classified as appropriate. However, of the remaining 30% of
PCIs performed for non-acute indications, 12% were deemed inappropriate and 38%
were classified as uncertain appropriateness. These non-acute procedures were utilized
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for patients with no angina, low-risk ischemia on noninvasive stress testing, or patients
who had received suboptimal medical therapy. Finally, use of non-acute procedures
varied substantially between hospitals, ranging from 0% to 50%. These findings suggest
that, while PCI may be used appropriately in the context of AMI, the increasing
availability of PCI may allow for increased utilization of PCI in non-acute situations,
exposing patients to excess and unnecessary risk and contributing to rising healthcare
costs.

Hospital PCI Volume
The increasing number of available PCI programs may also affect quality of care
due to changes in volume of PCIs performed at individual hospitals. From 2001 to 2009,
the proportion of STEMI patients initially admitted to hospitals with high volume of PCI
increased from 62.4% to 89.7%, while the percentage of STEMI patients admitted to lowvolume centers fell from 31% to 4.9%; additionally, patients admitted to non-PCI
hospitals and transferred to high-volume PCI hospitals decreased from 17.6% to 13.1%.13
The 2011 American College of Cardiology Foundation / American Heart
Association Task Force on Practice Guidelines and the Society for Cardiovascular
Angiography and Interventions (ACCF/AHA/SCAI) class I recommendations state that,
for both emergent and elective PCI, individual operators should perform at least 75 PCI
procedures per year at institutions that perform at least 400 procedures per year.14 These
recommendations apply for patients with STEMI, NSTEMI, and UA, though the
guidelines for STEMI also indicate that procedures should optimally occur at institutions
that perform at least 36 primary PCI procedures specifically for STEMI each year. These
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guidelines were developed due to evidence that treatment at higher-volume hospitals is
associated with improved patient survival.15-17 For example, in a study using data from
the National Registry of Myocardial Infarction, patients who were admitted to hospitals
with the highest volume of angioplasty per year had a 28% lower mortality rate than
those who were admitted to hospitals with the lowest volume, a relationship that persisted
even after adjusting for multiple factors, including volume of patients with AMI at each
hospital.15 Similarly, Post et al. analyzed 10 studies on the association between PCI
volume and mortality.16 The authors report 13% in-hospital mortality (an odds ratio of
0.87) for patients who underwent PCI at a high-volume hospital compared with those
who underwent the procedure at a low-volume hospital. Nonetheless, recent studies
demonstrate that such an association did not persist beyond an annual volume of 610
patients.17 While these studies have not identified specific causes for the association
between hospital volume and outcomes, some proposed explanations are that greater
experience develops experts who can perform the procedure with better outcomes, or
alternatively, that hospitals with the best results draw more patients.16 Although studies
have not investigated the impact of the increasing number of PCI hospitals on the volume
of PCIs, it follows that increased availability of PCI hospitals will dilute the volume of
PCIs performed at each hospital, thereby potentially increasing mortality rates.

Time to Treatment
With the creation of new PCI facilities, several studies have examined time to
treatment as a quality metric. The 2007 ACC and AHA guidelines state that patients with
STEMI should be treated with primary PCI within 90 minutes of their first medical
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contact.18 However, of patients with STEMI who were transferred for PCI in 2005, only
4% were treated within 90 minutes,19 though more recent data indicate that this number
has increased to 17%.20 Studies that have evaluated the impact of growing numbers of
PCI hospitals on treatment times have demonstrated little improvement. Concannon et al.
found that patients with AMI in 2008 could arrive at the nearest PCI hospital within a
median of 25.7 minutes, a 24 second improvement as compared to travel time in 2004,
although the study did find a more significant improvement in travel time of up to 4
minutes in areas with low baseline rates of access to PCI.3 Similar studies done for
patients requiring cardiac surgery have shown that travel time to cardiac surgery centers
also changed little between 1993 and 2004 despite significant increases in available
facilities, from 17 minutes in 1993 to 14 minutes in 2004, with the greatest effect again
occurring for patients living in rural areas.5 These findings suggest that the establishment
of new PCI programs has not contributed to substantial decreases in time to treatment for
patients with AMI.

Outcome Measures
Finally, many studies have focused on differences in patient outcomes, such as
mortality and readmission, for patients presenting to PCI versus non-PCI hospitals, with
conflicting results. In their 1998 study, Krumholz et al. demonstrated that mortality rates
at 30 days and at 3 years post-admission were similar for patients admitted to Connecticut
hospitals with and without on-site cardiac catheterization facilities, with 3-year mortality
rates of 45.1% and 44.5%, respectively.8 Alter et al. confirmed these findings in a
population of patients with AMI treated in Ontario in the same timeframe, demonstrating
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that 5-year survival rates were similar among patients presenting to hospitals with and
without on-site revascularization facilities.7 However, this work was done for patients
admitted between 1992-1993 in 2 specific regions, rather than on a national level.
In a more recent study, Chen et al. demonstrated that Medicare patients admitted
to PCI hospitals between 2004 and 2006 had significantly lower 30-day risk-standardized
mortality rates (RSMRs) compared with patients admitted to non-PCI hospitals (15.1%
versus 20.7%, respectively).10 However, further hospital-level analyses demonstrated that
while PCI hospitals had lower mortality rates on average than non-PCI hospitals (16.1%
versus 16.9%), quality of PCI and non-PCI hospitals varied across regions, such that
mortality rates were not consistently lower at PCI hospitals. For example, in 37 of 295
regions, mortality rates at local non-PCI hospitals were equal to or lower than the
mortality rates at PCI hospitals. In many regions, differences in mortality rates between
PCI and non-PCI hospitals were minor, with differences of less than 1.5% between
hospitals. These findings suggest that the quality of PCI and non-PCI hospitals varies
across the U.S., such that non-PCI hospitals may provide superior care to PCI hospitals in
some areas, despite the greater resources and capabilities available to PCI hospitals. It is
therefore important to evaluate whether it is worthwhile to invest in new PCI facilities, if
these hospitals do not provide uniformly better care than their non-PCI counterparts.
Factors that affect the quality of care at such institutions should be studied in more detail.
Similar discrepancies exist between studies of hospital readmission rates at PCI
and non-PCI hospitals. Krumholz et al. demonstrated that while 3-year all-cause
readmission rates were 4.6% lower for patients admitted to hospitals with catheterization
facilities than to those without, readmission rates for cardiovascular procedures were
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similar between hospitals.8 Other patient-level outcome measures, such as median length
of stay and mean number of days in the hospital during the subsequent 3 years after
admission were similar among patients admitted to hospitals with and without
catheterization facilities. In contrast, Alter et al. showed a 9% decrease in 5-year event
rates, including readmission for cardiac causes and all-cause emergency department (ED)
visits for patients admitted to hospitals with revascularization facilities as compared to
those without these capabilities, although the study found no significant difference in
readmissions for AMI.7 Interestingly, the authors attributed the decrease in 5-year event
rates at catheterization-capable hospitals to hospital teaching status rather than
catheterization capability, as patients admitted to teaching hospitals were more likely to
be followed by cardiologists after their initial admission as compared to patients admitted
to non-teaching hospitals, regardless of hospital catheterization capability status.
Importantly, the variation in outcomes between PCI and non-PCI hospitals was not
attributable to differences in utilization rates of invasive cardiac procedures at the
different hospitals, and rates of revascularization after hospitalization did not differ
significantly between the 2 groups.

Cost of Care
From 2004 to 2008, the establishment of 251 new PCI programs added between
$2 to $4 billion in costs to the U.S. healthcare system.3 As discussed above, the available
evidence suggests that recent investment in new PCI programs has not resulted in greater
access to PCI, and PCI hospitals do not offer conclusively better patient outcomes than
do non-PCI hospitals. These equivocal data lead to questions about the associated costs of
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care at PCI hospitals compared with non-PCI hospitals. Apart from the fixed cost of
building new PCI facilities,3 little is known about the subsequent cost of care for patients
admitted with AMI to PCI hospitals versus non-PCI hospitals.
Previous studies have measured cost in several ways, the most common of which
include hospital charges, cost-to-charge ratios, and estimated payments for Medicare
patients. These methods are discussed in detail in the 2012 Cost Measure Methodology
Report prepared by the Yale-New Haven Hospital Center for Outcomes Research and
Evaluation,21 but they are summarized here. Hospital charges are the prices set by a
hospital for different services. These prices are determined by a combination of hospital
expenses, profit goals, competition, and the need to offset uncompensated care. As a
result, higher hospital charges may represent increased use of resources, higher fixed
costs, or a combination of both. Alternatively, cost-to-charge ratios are ratios of hospital
expenses to patient and operating revenue. These are often used to convert hospital
charges to estimated costs. Finally, payments for Medicare patients represent Medicare
reimbursement to hospitals for the care of Medicare patients, calculated using Medicare
claims data from the Centers for Medicare and Medicaid Services (CMS).
In an early study by Krumholz et al., the authors examined hospital costs using
hospital charge records for patients admitted to Connecticut hospitals and cost-to-charge
ratios determined from the annual Medicare Cost Report for each hospital.8 Despite
adjustments for patient characteristics, the authors found no significant difference in the
cost of hospitalization by catheterization capability of the index (i.e. initial) hospital, with
a mean of $18,287 for patients admitted to catheterization hospitals and $17,012 for
patients admitted to non-catheterization hospitals. Similarly, the authors calculated a 3-
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year cost of $34,445 for patients admitted to catheterization hospitals and $32,565 for
patients admitted to non-catheterization hospitals, an insignificant difference.
Nevertheless, upon further evaluation of patients who underwent cardiac catheterization
during their index hospitalization, those who were initially admitted to noncatheterization hospitals but transferred to catheterization hospitals incurred higher costs
than those initially admitted to catheterization hospitals, with a difference in
hospitalization cost of approximately $6,951. Patients who underwent percutaneous
transluminal coronary angiography (PTCA), CABG surgery, both PTCA and CABG, or
no procedure did not incur significantly different costs if admitted to either type of
hospital. In conjunction with the rest of the paper’s findings discussed above, the authors
concluded that higher rates of catheterization but lower readmission rates at
catheterization hospitals contribute to equalizing the 3-year cost of care for patients
admitted to catheterization hospitals compared with non-catheterization hospitals.
A similar study conducted by Every et al. in 1997 evaluated cost of care for
patients admitted to catheterization and non-catheterization hospitals in Seattle,
Washington from 1988 to 1994.22 In contrast to the previous study, the authors found that
patients admitted to catheterization hospitals had higher 3-year cumulative costs than
patients admitted to non-catheterization hospitals by approximately $2500 per patient.
However, the authors found higher procedure rates on average than those reported in the
study by Krumholz et al., suggesting that there may exist geographical variation in the
effect of hospital catheterization capability on cost of care depending on the extent of
cardiac catheterization utilization.
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In a more recent study by Concannon et al., the authors constructed a model to

investigate the cost of various strategies to improve access to PCI by assessing patient
triage and resource utilization.23 The authors compared the cost of a hospital-based
strategy, by which hospitals constructed and staffed new PCI laboratories, with an
emergency medical services (EMS) strategy, by which patients with STEMI were
transported by EMS to existing PCI hospitals. These scenarios were also compared to a
simulated baseline case, using a standard protocol whereby EMS transported patients to
the nearest hospital, regardless of PCI capability. The authors found that when hospitals
constructed new PCI facilities, part-time laboratories resulted in a cost of $30,399 per
quality-adjusted life year (QALY) and full-time laboratories resulted in a cost of $14,765
per QALY. While these costs are lower than the costs of other accepted life-saving
therapies, the authors also found that a strategy in which EMS diagnosed patients in the
field and transported them directly to PCI hospitals resulted in a cost of $506 per QALY.
Due to the costs associated with EMS diagnosis and transport, the authors added an
additional $1000 per diverted patient to their cost model. The EMS strategy remained
most cost-effective until the price per diverted patient entered in the model was increased
above $19,769 or the expected benefit was decreased by 55%. These findings suggest
that the construction of new PCI facilities requires a substantial fixed cost that is offset by
increasing the number of patients with access to PCI. However, the EMS strategy can be
established with considerably lower costs up front, though it necessitates reliability of
EMS staff to identify patients with STEMI.
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Context
Given that the growing number of PCI hospitals has not increased access to care,
and that despite greater resources and capabilities, PCI hospitals may provide inferior
care to non-PCI hospitals in some areas, it is important to understand the differences in
cost of care between PCI hospitals and non-PCI hospitals. As described above, few
studies have characterized these costs, and to our knowledge, none have done so on a
national level. Results from this research may inform practices and policies influencing
the conversion of non-PCI hospitals to PCI hospitals and the implementation of a
regionalized system of AMI care.
Regionalization is the adoption of a national policy modeled on trauma care
through which patients with STEMI would be taken directly to designated STEMI centers
with PCI capability, rather than being admitted to potentially closer non-PCI community
hospitals.24 This strategy would include diagnosis of STEMI by EMS in the field with
direct transport to PCI hospitals or transport to non-PCI hospitals with immediate transfer
to PCI facilities. Many cardiovascular experts have supported this approach to AMI care,
with the goal of improving time to triage and appropriate treatment. However, there has
been little direct evidence that regionalization will improve outcomes or that it will be
financially sustainable for all hospitals.25
Proponents of regionalization of AMI care argue that avoiding admissions to nonPCI hospitals will increase the likelihood of receiving primary PCI over fibrinolysis and
will improve door-to-balloon time.25 While patients who present to non-PCI hospitals
may be treated with fibrinolysis immediately, shortening time to treatment, some studies
have shown that primary PCI is associated with improved outcomes compared with
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fibrinolytic therapy in patients with STEMI, even when treatment is delayed due to interhospital transfer.26 For example, in their meta-analysis of 6 large clinical trials, Dalby et
al. found a 42% reduction in the combined outcomes of death, reinfarction, and stroke
within 30 days in patients with STEMI who were transferred for primary PCI compared
with those who received on-site thrombolysis at non-PCI hospitals, despite delays of
approximately 70-100 minutes. In Minnesota, a regionalized system was established in
which 30 community hospitals referred patients with STEMI to a central PCI hospital.27
Through this system, patients located up to 210 miles from the PCI hospital achieved
median door-to-balloon times of 120 minutes and although this time did not meet the goal
of 90 minutes, in-hospital mortality was only 4.2%.
Delay in time to treatment is one of many barriers to regionalization. Researchers
have also argued that low risk patients may not benefit from primary PCI compared with
fibrinolytic therapy,28 and that transferring these patients to a PCI hospital negates any
incremental benefit of treatment with PCI.29-30 Similarly, hospital PCI volume may not
play as large a role as previously anticipated; if all PCIs were to be transferred from lowto high-volume hospitals, 800 transfers would be required to avoid 1 death.31 Moreover,
regionalization would require some concessions in patient autonomy that may hinder
community acceptance; patients may not want to be transferred to distant PCI hospitals,
where their admission may result in financial burdens for themselves, their families and
friends.25
The impact of regionalization on cost of care is also a contentious topic.
Noteworthy obstacles include loss of revenue and cardiac expertise in non-PCI hospitals,
and the potential for increased cost of care as more patients are treated at academic
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institutions. The potential loss of revenue for non-PCI hospitals is substantial, as patients
with STEMI often require additional post-hospitalization services, including noninvasive
imaging and subsequent catheterization.32 Pottenger et al. note that the conversion to a
regionalized system is likely to impact Medicare disproportionately, as the majority of
patients with STEMI are elderly.25 Additionally, systems such as pay-for-performance
will need to be revised to account for quality measures such as transfer times and to
address provision of care by multiple providers for each patient. For example, Pottenger
et al. question whether referring non-PCI hospitals would receive a percentage of the
payment for each patient transferred to the regional PCI hospital, and whether such
payments would be sufficient to compensate for the loss of revenue from previously
performed procedures.
While the issue of cost is multifaceted, this thesis contributes to the discussion by
focusing on payment for the care of patients with AMI from the perspective of Medicare.
This contribution is substantial, as Medicare is responsible for a large proportion of
hospitalizations for patients with AMI. For example, in 2010, Medicare paid for
approximately 40% of all-cause hospitalizations nationally, and nearly 90% of
hospitalizations for patients 65 years or older.33 Finally, though the debate on
regionalization has centered on care for patients with STEMI, the proposed system will
likely impact patients with NSTEMI if implemented, so it is important to consider
patterns of care for these patients.
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Conceptual Model
This work is predicated on the following rationale: Admission to PCI hospitals
may be associated with higher costs for patients with AMI due to higher rates of inpatient
procedures compared with non-PCI hospitals.6-10 Alternatively, non-PCI hospitals may be
associated with higher costs for patients with AMI for several reasons. For example,
admissions to non-PCI hospitals that require transfer to PCI hospitals for urgent
procedures result in 2 payments from health insurers, 1 for each admission. Additionally,
patients discharged from non-PCI hospitals without transfer for PCI may later undergo
PCI during subsequent admissions or in the outpatient setting. In fact, the costs associated
with transfers and deferred procedures for patients admitted to non-PCI hospitals may
balance the cost associated with higher procedure rates at PCI hospitals.

Research Objective
In light of the conceptual model described above, we sought to characterize the
cost of care provided by PCI versus non-PCI hospitals for Medicare patients presenting
with AMI. We compared payments made at the hospital-level for Medicare patients over
a 30-day episode of care to account for the costs of both hospitalizations in the case of a
transfer and the costs of follow-up care, including non-acute procedures. In an effort to
better understand the reasons underlying hospital-level costs of care, we also conducted
secondary patient-level analyses examining rates of patient transfer and coronary
revascularization, including both PCI and CABG surgery, for patients presenting to PCI
and non-PCI hospitals.
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STATEMENT OF PURPOSE, HYPOTHESIS AND SPECIFIC AIMS
Statement of Purpose
The purpose of this study is to compare payments made at the hospital-level for
Medicare patients over a 30-day episode of care between PCI hospitals and nonPCI hospitals in order to better understand the cost implications of patterns of care
for patients with AMI.

Hypothesis
Greater utilization of PCI at PCI hospitals compared with non-PCI hospitals and
increased rates of transfer and post-acute care procedures at non-PCI hospitals
compared with PCI hospitals results in similar payments to PCI and non-PCI
hospitals for the care of Medicare patients with AMI.

Specific Aims
•

To calculate and compare hospital-level risk-standardized payments for
Medicare patients with AMI over a 30-day episode of care between PCI and
non-PCI hospitals;

•

To calculate and compare index admission procedure rates (PCI and CABG),
transfer rates, and 30-day subsequent revascularization rates for Medicare
patients with AMI between PCI and non-PCI hospitals.
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METHODS
Data Sources
To identify our cohort, we used a 2008 Chronic Condition Warehouse (CCW)
dataset of Medicare administrative claims to identify 100% of fee-for-service (FFS)
beneficiaries 65 years or older who had an inpatient admission with a principal discharge
diagnosis of AMI as identified using International Classification of Diseases, 9th revision
(ICD-9) codes 410.xx, excluding those with 410.x2. The CCW data included claims data
from the 7 Standard Analytic Files (inpatient, outpatient, skilled nursing facility, home
health, hospice, carrier [physician/supplier Part B items], and durable medical
equipment). We used this data in conjunction with publicly available fee schedules from
CMS and Final Rules published in the Federal Register to calculate the total payment for
the episode of care, including payments for the index admission and post-discharge
payments for readmissions, other post-discharge inpatient care, outpatient services,
skilled nursing facilities, home health, physician, clinical laboratory, or ambulance
services, and prosthetics, orthotics, and other medical supplies. We used January 2009
CCW data to calculate post-acute care payments for patients discharged from their index
admission in December 2008. We obtained institutional review board approval including
waiver of the requirement for participant informed consent, through the Yale University
Human Investigation Committee.
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Cohort
The study cohort included Medicare FFS beneficiaries, ages ≥ 65 years,
hospitalized between January 1 – December 31, 2008, with a principal discharge
diagnosis of AMI as defined above. We required that all patients had both Part A and Part
B coverage in both the year prior to the index admission and during the 30-day episode of
care payment window. We excluded the following groups of patients: (1) patients who
were admitted and discharged on the same or next day and did not die or get transferred,
as these patients likely did not suffer a clinically significant AMI, (2) patients with
inconsistent or unknown vital status (e.g. if the date of death preceded the date of
admission), (3) patients with unreliable data (e.g. if the age was greater than 115 or the
gender was discordant on the index admission claim and the denominator file), (4)
patients discharged against medical advice, as hospitals had limited opportunity to
provide appropriate care, (5) hospice patients, (6) patients transferred to federal hospitals,
as we did not have claims data for these hospitals, so including these patients would
underestimate payments, and (7) patients with missing Medicare-Severity Diagnosis
Related Group (MS-DRG) code or MS-DRG weight, as we could not calculate an index
admission payment for these patients.
For patients with multiple hospitalizations for AMI during this time frame, we
randomly selected 1 hospitalization per patient. We chose this method because payments
for repeat AMI admissions may differ from payments for patients with a first AMI, due to
differences in management. Choosing only first AMI admissions could overestimate
payments, while choosing only repeat admissions could underestimate payments.
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Hospital Classification
We classified hospitals as PCI- or non-PCI-capable based on evidence that they
performed PCIs in the year prior to the index admission. Using billing, we defined PCI
hospitals as those hospitals that had billed Medicare for 10 or more PCI procedures in
2007, using ICD-9 procedure codes 36.01, 36.02, 36.05, 36.06, 36.07, 00.66 and 17.55
for PCI. Hospitals for which PCI status could not be determined (e.g. those with new
hospital IDs in 2008) were excluded from the analysis (n=13 hospitals).

Primary Outcome
Our primary outcome was 30-day episode of care risk-standardized payments
(RSPs) at the hospital level. We calculated total payment for the 30-day episode of care
by summing all payments from the time of index admission through 30 days postadmission. For patients who were transferred, we considered the consecutive admissions
as a single hospitalization with the 30-day episode beginning with the index admission.
All payments for Medicare patients incurred during the second admission as well as
during the full 30-day episode were attributed to the initial admitting hospital,
constituting 1 episode of care (Figure 1).
We chose to include payments for an episode of care window rather than the acute
hospitalization alone for several reasons. Hospitalizations occur due to new illnesses or
exacerbation of pre-existing illnesses that require follow-up care after discharge. Care
decisions made during the hospitalization likely affect care requirements when patients
leave the hospital. It follows that payments for care provided soon after hospital
discharge in part reflect variation in patient management during admission, and may be
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attributed to the index hospital as part of a continuous episode of care. We chose 30 days
because it is a preset window that is consistent with publicly reported outcomes measures
from CMS, such as AMI RSMR and risk-standardized readmission rates (RSRR).
We used publicly available fee schedules from CMS to calculate payments for
claims that occurred in care settings reimbursed under a fee schedule. Reimbursement
rates and weights for each care setting were from fiscal year, rate year, or calendar year
2008 or 2009 depending on the care setting, and were identified in either Final Rules
published in the Federal Register or fee schedules listed on the CMS website. For those
care settings not reimbursed using a CMS fee schedule, we obtained the data necessary to
calculate payments from applicable CMS Final Rules or via the CMS website (e.g. base
payments and conversion factors, MS-DRG weights, wage indexes, and average length of
stay). We also used the Medicare Enrollment Database (EDB) to obtain information on
enrollment, date of birth, and post-discharge mortality status.

Figure 1. Episode of care for transferred patient.

AMI denotes acute myocardial infarction.
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Standardizing Payments
Medicare reimburses providers using several different mechanisms depending on
the care setting. For acute inpatient stays, the Inpatient Prospective Payment System
(IPPS) payments for each patient begin with an operating and capital base payment,
which are held constant over a given fiscal year and reflect the cost of delivering care to a
patient for an average Medicare hospitalization. Where applicable, these base payments
are then adjusted for geographic differences in wages and cost of living. Geographically
adjusted payments are then multiplied by the weight associated with a patient’s MSDRG. The MS-DRG accounts for the patient’s principle discharge diagnosis, up to 8
secondary diagnoses, up to 6 procedures performed during the hospitalization,
complications, age, gender, and comorbidities. Diagnoses that involve greater resource
utilization are assigned higher MS-DRG weights. For hospitals that qualify, additional
adjustments are made for the cost of teaching medical trainees (indirect medical
education) and caring for low-income patients (disproportionate share policy payments).
Where applicable, adjustments are made for short-stay patients and patient discharge
destination. In the case of extraordinarily costly patients, an outlier payment may also be
applied.
Medicare reduces payments when patients are transferred to another IPPS hospital
and have a length of stay at least one day less than the geometric mean length of stay for
the MS-DRG. Therefore, for transferred patients, the index hospital is paid a per diem
rate. However, for stays at the index hospital that are equal to or longer than the
geometric mean length of stay for the MS-DRG, the index hospital receives a full MSDRG payment. For transferred patients, we assigned the per diem or full MS-DRG
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payment to the index hospital and added it to the payment for the receiving hospital to
generate the full payment for the index admission.
For each care setting, we standardized payments by calculating a payment that
removes the influence of Medicare geographic and policy adjustments in order to isolate
the portion of payment that reflects care decisions. To calculate standardized payments
for acute inpatient stays, we multiplied the operating and capital base payment rates by
the MS-DRG weight for each claim. We then accounted for transferred patients as
described above. Finally, we added any applicable outlier payments to arrive at our total
standardized inpatient payment. Payment diagrams for each of the care setting and our
approach to standardizing payments where applicable are shown in Supplementary
Figures 1-17.
When the data did not allow for the removal of geographic adjustments, we used
the CMS fee schedule data to calculate an average payment and uniformly applied it
across all geographic areas. For example, for laboratory services, where Medicare
reimburses each state at different amounts, we averaged the payment for an item across
all states and replaced the state-specific payment amount for that item in a patient’s claim
with the average payment.
We then arrived at a total payment for each episode of care by summing our
standardized payments for all applicable care settings during a patient’s 30-day episode
of care. We included payments that began during a patient’s 30-day episode of care but
ended after by applying a prorated amount (Supplementary Table 1). For example, if a
patient were admitted to a skilled nursing facility on day 25 of the episode of care
window and remained in the facility until day 40, we calculated the payment for the
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entire 16-day period and then divided it by 16 to obtain a daily payment amount. We then
multiplied that amount by the number of days the patient was in the care setting during
the 30-day episode of care payment window (6 in the example above).

Calculating RSPs
We calculated the RSP for each hospital using 2-level hierarchical generalized
linear models that adjust for patient demographics, such as age and clinical
characteristics, including comorbid conditions identified in claims for acute inpatient
hospital stays, hospital outpatient care, and physician, radiology, and laboratory services
for the 12 months prior to the index admission as well as select conditions indicated by
secondary diagnoses codes on index admission. Hospital level random intercepts were
included to account for the clustering, or nonindependence, of patients within hospitals,
and to capture hospital-level signal.
We used CMS Condition Category groups (CCs) to define the comorbid riskadjustment variables. Candidate risk-adjustment variables were selected for the model
based on clinical coherence and strength of association in the same manner as for the
CMS AMI mortality measure.34 We then selected final risk-adjustment variables by
bootstrapping multiple stepwise regressions and included those variables that came into
the model over 90% of the time. We did not risk-adjust for diagnoses that may be
complications of care during the index admission because although complications may
contribute to higher costs and payments, they represent potential differences in payment
that are influenced by hospital actions and such differences should be captured by the
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payment measurement. Additionally, we risk-adjusted for the patients’ age and a history
of PCI and/or CABG.
We used the following strategy to calculate the hospital-specific RSPs. We
calculated these payments as the ratio of predicted AMI payment to expected AMI
payment, and multiplied by the national unadjusted average AMI payment. The predicted
AMI payment for each hospital was estimated using its patient mix and an estimated
hospital-specific intercept. The expected AMI payment for each hospital was estimated
given the same patient mix but the average intercept among all hospitals in the sample.

Secondary Outcomes
We calculated rates of PCI and CABG, transfer rates, and rates of
revascularizations that followed the inpatient admission (subsequent revascularizations),
including PCI and CABG performed during readmissions and PCI performed in the
outpatient setting within 30 days of admission for patients who began their episode of
care at PCI and non-PCI hospitals. We defined transferred patients as those patients who
were either transferred between hospitals or discharged from 1 acute-care hospital and
admitted to a different acute-care hospital on the same or next day, regardless of the
discharge disposition listed on the claim. We identified patients who underwent PCI
either during index admission or readmission within the 30-day episode of care using
ICD-9 codes 36.01, 36.02, 36.05, 36.06, 36.07, 00.66 and 17.55, CABG using ICD-9
codes 36.1x, and outpatient PCI using Current Procedural Terminology (CPT) codes
92973, 92980, 92981, 92982, 92984, 92995 and 92996.
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Statistical Analysis
We performed a hospital-level analysis comparing the mean RSP for PCI
hospitals with the mean RSP for non-PCI hospitals. We then performed the following
patient-level analyses. We first calculated and compared procedure (PCI and CABG) and
transfer rates for patients at PCI and non-PCI hospitals. Additionally, we calculated and
compared the rate of subsequent revascularizations that occurred after the index
discharge but during the 30-day episode of care for patients admitted to PCI versus nonPCI hospitals. Procedures for patients who were readmitted within the 30-day episode of
care but whose admissions extended beyond the end of the 30-day window were included
in the subsequent revascularization outcome. A t-test was used to compare RSPs and χ2
tests were used for dichotomous variables. We did not pre-specify a threshold to define
clinically significant differences in RSP. We considered differences statistically
significant when P values were less than 0.05. All analyses were conducted using
Stata/IC statistical software, version 11.1.

Authorship Contributions
Ms. Gal Ben-Josef conceived of and designed this project along with Dr.
Susannah M. Bernheim, with guidance from Dr. Harlan M. Krumholz. Ms. Ben-Josef
conducted an extensive review of the literature and was responsible for running
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statistical analyses, and Ms. Lesli S. Ott conducted the final analyses and generated the

	
  

	
  

27

final data. Ms. Ben-Josef was responsible for interpreting the data and formulating
implications along with Drs. Susannah M. Bernheim, Joseph S. Ross, and Harlan M.
Krumholz. All authors participated in discussions on the integrity of the data and
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RESULTS
Patient Characteristics
Of the 180,375 AMI hospitalizations in 2008 included in this study, 137,427
(76.2%) were admissions to 1,415 PCI hospitals and 42,948 (23.8%) to 2,716 non-PCI
hospitals. Baseline characteristics for patients initially admitted to PCI hospitals versus
non-PCI hospitals are shown in Table 1. Of note, patients presenting to PCI hospitals
were younger than those presenting to non-PCI hospitals, with patients age 85 or older
composing only 26.3% of patients admitted to PCI hospitals as compared to 40.6% of
those admitted to non-PCI hospitals. A greater percentage of patients presenting to PCI
hospitals had previously undergone PCI as compared with those presenting to non-PCI
hospitals (8.4% v. 5.3%, respectively), but a smaller percentage of patients admitted to
PCI hospitals had previously undergone CABG (5.7% v. 7.1%, respectively). In addition,
28.6% of patients presenting to PCI hospitals had a history of congestive heart failure
compared with 39.9% at non-PCI hospitals, and only 15.2% of patients presenting to PCI
hospitals had a history of dementia as compared with 24.7% at non-PCI hospitals.

RSPs and Secondary Analyses
PCI hospitals had a higher mean 30-day RSP than non-PCI hospitals (PCI
$20,340; non-PCI $19,713; P<0.001). The range of RSP was similar between PCI and
non-PCI hospitals (PCI $15,251-$27,317; non-PCI $16,769-$24,597) (Figure 2).
To better understand the factors contributing to this difference in hospital-level
payments, we identified the following patient-level patterns of care, shown in Table 2.
Patients presenting to PCI hospitals had lower transfer rates (2.2% v. 25.4%, P<0.001)
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than those presenting to non-PCI hospitals. Patients presenting to PCI hospitals had
higher PCI rates (39.2% v. 13.2%, P<0.001) and higher CABG rates (9.5% v 4.4%,
P<0.001) during the index admission than those presenting to non-PCI hospitals. Finally,
the rate of subsequent revascularization within 30 days of the initial hospitalization was
lower among patients who initially presented to PCI hospitals than to non-PCI hospitals
(0.15%

v.

0.27%,

P<0.0001).

However,

these

results

represent

subsequent

revascularization rates for all patients, including those who were not eligible for postacute care. The relationship persisted when data were limited to only those patients who
were eligible for post-acute care, with a rate of subsequent revascularization of 0.17%
among patients presenting to PCI hospitals compared with 0.31% among patients
presenting to non-PCI hospitals (P<0.001).
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Table 1. Baseline patient characteristics of patients with AMI in 2008, stratified by initial
admission to PCI or non-PCI hospitals.
Overall

PCI

Non-PCI

(N=180,375)

(N=137,427)

(N=42,948)

N

(%)

N

(%)

N

(%)

Age (65-74)

56,102

31.1

46,640

33.9

9,462

22.0

Age (75-84)

70,769

39.2

54,709

39.8

16,060

37.4

Age (≥ 85)

53,504

29.7

36,078

26.3

17,426

40.6

History of PCI

13,858

7.7

11,583

8.4

2,275

5.3

History of CABG

10,824

6.0

7,772

5.7

3,052

7.1

56,486

31.3

39,369

28.6

17,117

39.9

38,210

21.2

28,787

20.9

9,423

21.9

3,242

1.8

2,666

1.9

576

1.3

49,155

27.3

36,876

26.8

12,279

28.6

1,700

0.9

1,367

1.0

333

0.8

151,080

83.8

114,356

83.2

36,724

85.5

7,183

4.0

5,306

3.9

1,877

4.4

Variable

Congestive Heart Failure
(CC 80)
Angina Pectoris/Old Myocardial
Infarction (CC 83)
Heart Infection/Inflammation,
Except Rheumatic (CC 85)
Valvular and Rheumatic Heart
Disease (CC 86)
Congenital Cardiac/Circulatory
Defect (CC 87-88)
Hypertension and Hypertension
Complications (CC 89-91)
Metastatic Cancer/Acute Leukemia
and Other Major Cancers (CC 7-8)
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Table 1. (continued)
Diabetes and Diabetes
75,502

41.9

56,564

41.2

18,938

44.1

8,974

5.0

6,462

4.7

2,512

5.8

11,246

6.2

8,696

6.3

2,550

5.9

130,381

72.3

100,660

73.2

29,721

69.2

81,382

45.1

60,561

44.1

20,821

48.5

26,437

14.7

19,359

14.1

7,078

16.5

69,629

38.6

50,973

37.1

18,656

43.4

6,733

3.7

4,815

3.5

1,918

4.5

Dementia (CC 49)

31,545

17.5

20,932

15.2

10,613

24.7

Drug/Alcohol Psychosis (CC 51)

2,104

1.2

1,624

1.2

480

1.1

17,830

9.9

14,314

10.4

3,516

8.2

7,958

4.4

5,625

4.1

2,333

5.4

Complications
(CC 15-19, 119-120)
Protein-Calorie Malnutrition
(CC 21)
Other Significant Endocrine and
Metabolic Disorders (CC 22)
Obesity/Disorders of Thyroid,
Cholesterol, Lipids (CC 24)
Other Gastrointestinal Disorders
(CC 36)
Osteoporosis and Other
Bone/Cartilage Disorders (CC 41)
Iron Deficiency and
Other/Unspecified Anemias and
Blood Disease (CC 47)
Delirium and Encephalopathy
(CC 48)

Drug/Alcohol Abuse/Dependence
(CC 52-53)
Severe Mental Illness (CC 54-55)
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Table 1. (continued)
Reactive and Unspecified
5,505

3.1

3,566

2.6

1,939

4.5

19,060

10.6

13,330

9.7

5,730

13.3

27,561

15.3

20,703

15.1

6,858

16.0

45,323

25.1

33,423

24.3

11,900

27.7

Other Lung Disorders (CC 115)

48,611

27.0

36,612

26.6

11,999

27.9

Legally Blind (CC 116)

1,351

0.8

929

0.7

422

1.0

Dialysis Status (CC 130)

4,035

2.2

3,199

2.3

836

1.9

Internal Injuries (CC 160)

1,672

0.9

1,279

0.9

393

0.9

Psychosis (CC 56)
Depression/Anxiety (CC 58-59)
Precerebral Arterial Occlusion and
Transient Cerebral Ischemia
(CC 97)
Vascular Disease and
Complications
(CC 104-105)

AMI denotes acute myocardial infarction; PCI, percutaneous coronary intervention; CABG,
coronary artery bypass graft; CC, condition category.

	
  

	
  

33

Table 2. Patient transfer rates, procedure rates, subsequent revascularization rates, and
30-day risk-standardized payment by PCI capability of the index hospital.

Hospital (N)
Volume (n)
Transfer Rate (%)
Index Admission PCI Rate (%)
Index Admission CABG Rate (%)
Subsequent Revascularizations (%)

Overall

PCI

Non-PCI

4,131

1,415

2,716

180,375

137,427

42,948

7.7

2.2

25.4

33.0

39.2

13.2

8.3

9.5

4.4

0.18%

0.15%

0.27%

19,928 (1,161)

20,340 (1,493)

19,713 (869)

30-Day Risk-Standardized Payment ($):
Mean (Standard Deviation)
PCI denotes percutaneous coronary intervention; CABG, coronary artery bypass graft.
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Figure 2. Distributions of 30-day risk-standardized payment by PCI capability of the
index hospital.

PCI denotes percutaneous coronary intervention.
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DISCUSSION
In this study of Medicare administrative claims, we found that PCI hospitals were
associated with slightly higher payments for an episode of care for patients with AMI
when compared with non-PCI hospitals. While the difference is fairly modest –
approximately $600 over a 30-day period – when spread over the hundreds of thousands
of beneficiaries with AMI each year, the cost implications are important. It is critical to
determine whether this extra cost provides extra value, either through improved clinical
outcomes such as mortality or readmission, or improved patient satisfaction, function, or
symptom burden.
There are a number of potential explanations for the difference in payments for
AMI episodes initiated at PCI versus non-PCI hospitals. To understand factors that may
account for the observed payment difference, we examined several patient-level patterns
of care for patients admitted to PCI versus non-PCI hospitals. We found that patients who
began their episode of care at PCI hospitals had higher PCI and CABG rates during the
index admission than those initially admitted to non-PCI hospitals. Procedure rates may
contribute considerably to higher payments. However, patients initially admitted to nonPCI hospitals had substantially higher transfer rates and subsequent revascularization
rates than patients initially admitted to PCI hospitals. Patients who are transferred accrue
the cost of 2 hospitalizations, which may in part balance the cost of higher procedure
rates at PCI hospitals. Similarly, the increased utilization of post-acute care resources by
patients admitted to non-PCI hospitals adds to the payment for the 30-day episode of care
initiated at non-PCI hospitals.
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The results of this study are consistent with the earlier study by Krumholz et al.,

discussed above, in which long term costs and outcomes were examined for patients
admitted to Connecticut hospitals with or without on-site cardiac catheterization
facilities.8 The authors found no significant difference in hospital costs in the 3 years
after the initial admission for patients admitted to hospitals with and without cardiac
catheterization capability. Despite similar findings, the study variables differed
substantially from those used in this study. This previous work was done for patients
admitted between 1992-1993 in a single state, and costs were defined by each patient’s
hospital charge record and each hospital’s Medicare cost-to-charge ratios. Conversely,
our study evaluated the hospital-level payment made for Medicare patients admitted
nationwide, and in the setting of growing numbers of PCI facilities in 2008.

Implications
Our finding that the cost of care at PCI and non-PCI hospitals is only modestly
different impacts recent discussions on regionalization of AMI care and the establishment
of new PCI programs. Many studies have considered whether regionalization of care
would benefit patients with AMI, but few, if any, have considered the cost implications
of such a change in patient management. If AMI care were to be regionalized, patients
with AMI who present to non-PCI hospitals would be immediately transferred to
specialty regional centers with the capacity to perform PCI, without admission to nonPCI hospitals. Our findings suggest that sending all patients directly to PCI hospitals is
not likely to substantially increase payment for Medicare patients admitted with AMI,
despite the possibility of increased PCI utilization. Since patients who present with AMI
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may benefit from more rapid access to PCI, and in light of our findings that payments to
PCI versus non-PCI hospitals do not differ dramatically, regionalization of AMI care may
provide a more efficient option for the treatment of these patients.
While this work demonstrates that transporting patients directly to PCI hospitals
may be economically feasible, our findings suggest that opening new PCI programs in the
absence of an organized system for regionalization of care is not a cost-effective strategy
for AMI care. As discussed above, access to PCI has not changed in recent years, despite
increased availability of PCI hospitals.1-4 This is in part explained by evidence that the
majority of hospitals establishing new PCI programs are those near hospitals that already
offer the same services.2,3 Moreover, increased availability of PCI has allowed for
increased use of PCI for non-acute indications, resulting in unnecessary procedures that
may put patients at undue risk.12 Hospitals struggling to keep up with the cost of new PCI
facilities may have an incentive to encourage PCI use. New PCI facilities have likely
resulted in a distribution of patients over increasing numbers of hospitals, lowering the
volume of PCI performed at each hospital and potentially impacting patient outcomes, as
higher volume of PCI has been associated with improved survival.15-17 Finally, growth in
the number of PCI hospitals has not led to improvements in time to treatment for AMI.3
This fund of knowledge suggests that increasing the absolute number of PCI hospitals has
not resulted in improved care for patients with AMI.
Despite these findings, the evidence on mortality and readmission rates at PCI and
non-PCI hospitals remains less clear. Recent studies have shown that although mortality
is lower on average for patients who present to PCI hospitals, there exists significant
variation in mortality rates among PCI hospitals across the country.10 Geospatial
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modeling has demonstrated a mortality advantage both for high-benefit patients who
were transported directly to PCI hospitals and for those transferred from the ED to PCI
hospitals, compared with patients who were transported to the nearest hospital and treated
with PCI or thrombolytics, depending on availability.35 Though this targeted PCI strategy
increased PCI use by 1.5 times compared to the closest hospital strategy and led to a
700% increase in patient volume at PCI hospitals, a strategy of universal PCI that
directed all patients to PCI hospitals resulted in the same mortality rate but increased PCI
use by 3 times and volume by over 1000%. These findings suggest that a regionalization
strategy that relies on EMS and ED services to triage patients may improve mortality
rates for patients with AMI while mitigating the economic impact on non-PCI hospitals
due to loss of patient volume.
In light of these data, our finding that PCI hospitals are modestly more costly to
Medicare than non-PCI hospitals suggests that investing in new PCI facilities may not be
worthwhile. Although the difference in cost is fairly small, building new PCI facilities
also requires a sizeable fixed cost that adds to the financial burden of PCI hospitals.3 As
the evidence discussed above suggests that greater numbers of PCI facilities have not
benefited patients, the extra cost of both construction and patient care yields limited
value. Importantly, modeling techniques have shown that a system that utilizes EMS to
transfer patients directly to existing PCI hospitals is of better value than constructing new
PCI facilities.23 Such a system would still allow patients to benefit from the potential
mortality advantage of PCI hospitals while avoiding the shortcomings of investing in new
PCI facilities.
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Limitations
This study has several limitations. First, this work examined payments made at
the hospital-level for Medicare patients over a 30-day episode of care. We did not
evaluate cost of care from the perspective of patients or hospitals through hospital
charges or cost-to-charge ratios. Therefore, we cannot comment on the differences in cost
of care between PCI and non-PCI hospitals from these perspectives. Second, we used
Medicare admission data only, and results may not be applicable to the general
population or other insurers given different payment structures. However, Medicare is the
country’s largest insurer and Medicare patients make up a large proportion of patients
with AMI. Third, we did not assess whether the modestly higher payment to PCI
hospitals contributes to better outcomes for patients, including decreasing mortality and
readmissions. The effect of admission to PCI versus non-PCI hospitals on patient
mortality and readmission requires further investigation.
Our analysis of transfers included only those patients who were admitted to the
initial presenting hospital and transferred to a second hospital; we were unable to
determine whether patients presented to the ED of 1 hospital before being transferred and
admitted to a second hospital. Our payment outcome did not account for the cost of the
ambulance for patients who were transported to the hospital or the cost of ambulance
transfer between hospitals during the index admission. Similarly, we did not include
payments for Medicare Part D drugs. Since patients who do not undergo PCI may rely
more heavily on medical management than those who undergo the procedure, excluding
these payments may lower the average payment for non-PCI hospitals, thus exaggerating
the overall difference in payments between PCI and non-PCI hospitals. However, given a
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payment window of only 30 days, the added cost of medications is likely not substantial.
Finally, our method of identifying patients who underwent PCI did not account for those
patients who underwent a procedure greater than 30 days after their initial admission.
Lastly, our study does not address the question of what types of patients were
more likely to be transferred from non-PCI hospitals in order to undergo PCI. Therefore,
we were not able to appreciate whether high-risk patients who presented to PCI and nonPCI hospitals were treated similarly. It is possible that high-risk patients may be
transferred less often due to their unstable condition. Since patients who presented to
non-PCI hospitals were generally older than those presenting to PCI hospitals, and
therefore at higher risk of complication during transfer, this may contribute in part to the
lower procedure rates attributed to non-PCI hospitals.

Conclusion
In conclusion, this study demonstrates that despite increased PCI and CABG rates
for patients who begin their 30-day episode of care at PCI hospitals, hospital-level
payments to PCI hospitals are only modestly higher than hospital-level payments to nonPCI hospitals for the treatment of AMI patients.
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SUPPLEMENTARY FIGURES AND TABLES
The following payment diagrams are adapted from the 2012 Cost Measure Methodology
Report prepared by the Yale-New Haven Hospital Center for Outcomes Research and
Evaluation21 and are initially derived from the MedPAC Payment Basics series, October
2007.

Figure 1. Payment and standardization method for the inpatient setting.

DRG denotes diagnosis related group; LOS, length of stay; IPPS, inpatient prospective payment system.
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Figure 2. Payment and standardization method for inpatient psychiatric facilities.

DRG denotes diagnosis related group; LOS, length of stay.

Figure 3. Payment and standardization method for inpatient rehabilitation facilities.

IRF denotes inpatient rehabilitation facilities; CMG, case-mix group; LOS, length of stay; ALOS, average
length of stay for CMG.
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Figure 4. Payment and standardization method for long term care hospitals.

LTCH denotes long term care hospital; DRG, diagnosis related group; LOS, length of stay.

Figure 5. Payment and standardization method for hospital outpatient services and community
mental health centers.

APC denotes ambulatory payment classification; SCH, sole community hospital. Note: APC measures
resource requirements of services; Hold Harmless payments are additional payments to hospitals (i.e.
cancer, children’s, non-SCH rural with <100 beds) that experience losses under the outpatient prospective
payment system compared to cost-based systems. †	
   This amount is adjusted for any modifiers such as
reduced or discontinued procedures.
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Figure 6. Payment and standardization method for comprehensive outpatient rehabilitation
facilities and outpatient rehabilitation facilities.

RVU denotes relative value unit; GPCI, geographic practice cost index. Note: RVUs account for the
relative costliness of the inputs used to provide services: clinician’s work, practice expenses, and
professional liability insurance expenses.

Figure 7. Payment and standardization method for ambulatory surgical centers.

ASC denotes ambulatory surgical center; APC, ambulatory payment classification.
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Figure 8. Payment for renal dialysis facilities.

RDF denotes renal dialysis facility. Note: A Renal Dialysis Prospective Payment System was implemented
in 2011.

Figure 9. Payment for rural health clinics and federally qualified health clinics.

RHC denotes rural health clinic; SNF, skilled nursing facility; FQHC, federally qualified health clinic.
Note: A FQHC prospective payment system is scheduled to be implemented in 2014.
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Figure 10. Payment for laboratory services.

Figure 11. Payment for ambulance services.

Figure 12. Payment for Part B drugs.

	
  

	
  

51

Figure 13. Payment and standardization method for skilled nursing facilities.

SNF denotes skilled nursing facility; RUG, resource utilization group. Note: RUG includes therapy and
service use, presence of certain medical conditions, and activity of daily living score.

Figure 14. Payment and standardization method for home health agencies.

HHA denotes home health agency; HHRG, home health resource group; DME, durable medical equipment;
POS, prosthetics and orthotics; PPS, prospective payment system. Note: HHRGs are comprised of clinical,
functional, and service utilization scores based on patient characteristics. HHA claims can include
DME/Prosthetics/O2 as well. Payments for those claim lines are calculated according to the DME/POS
payment formula.
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Figure 15. Payment and standardization method for hospice.

Figure 16. Payment and standardization method for physicians, physician extenders, social work
services.

RVU denotes relative value units; GPCI, geographic practice cost index; HPSA, health professional
shortage area.
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Figure 17. Payment for durable medical equipment, prosthetics and orthotics, and parenteral and
enteral nutrition.

DME denotes durable medical equipment; POS, prosthetics and orthotics; PEN, parenteral and enteral
nutrition. Note: Where applicable, Part B Drugs associated with DME claims were assigned the DME
infusion limit amount from the Part B Drugs fee schedule.
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Table 1. Example of included and excluded payments for a patient admitted on May 3
and discharged on May 8.
Claim
Type

Claim
Date

Admission
Type

Primary
ICD-9

Payment

Included
in Model?

Payment
Included
in Model

Carrier

5/25/3

N/A

410.91

$255.61

N

$0.00

Inpatient

5/35/4

Inpatient

5/45/8

Carrier
Carrier
Carrier
Carrier
Carrier

5/35/3
5/35/3
5/35/8
5/55/5
5/75/7

Admission

Transfer

N/A
N/A
N/A
N/A
N/A

410.71

$1,109.49

Y

$1,109.49

This inpatient AMI
(410.71) discharge
defines the
discharge date (5/8).

$8,008.15

Y

$8,008.15

785.0

$367.20

Y

$367.20

428.0

$6.59

Y

$6.59

410.71

$350.52

Y

$350.52

414.01

$225.75

Y

$225.75

296.30

$148.39

Y

$148.39

5/306/3

Readmission

410.71

$4,262.13

Y
(prorated)

Skilled
Nursing
Facility

6/36/21

Transfer

428.0

$1,652.28

N

TOTAL

$16,386.11

Starts prior to the
index admission and
ends within the
analytic period.
This inpatient AMI
(410.71) admission
defines the index
admission date
(5/3).

410.71

Inpatient

Comments

$3,409.70

$0.00

N/A
N/A
N/A
N/A
N/A
Payment is prorated
based only on days
in the 30-day postadmission period.
The amount
includes:
($4262.13/5) x 4 =
$3409.70.
This second AMI
(410.71) admission
does not count as an
index admission,
but as a
readmission.
Starts after the 30day post-admission
period.

$13,625.79

AMI denotes acute myocardial infarction.

	
  

